Clinical Trial of the Use of Ketamine in Treatment Resistant Depression

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the efficacy of the use of intravenous low-dose ketamine in the treatment of treatment-resistant depression (TRD), as well as the changes in Glutamate neurotransmission and inflammatory serum markers.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Institute of Neurology and Neurosurgery, Mexico
• Treatments: Ketamine

Criteria

Inclusion Criteria:

• Treatment-Resistant Depression (Failure to respond to two or more trials of antidepressant monotherapy or failure to respond to four or more trials of different antidepressant therapies)

• Acceptance of participation via the informed consent

Exclusion Criteria:

• Psychiatric comorbidity (except anxiety related disorders)

• Substance abuse or dependence in the previous 3 months

• Evidence of structural abnormalities in brain imaging

• Pregnancy

• Previous hypersensitivity to ketamine

• Heart failure or insufficiency

• Familial or personal history of psychosis

• Glaucoma

• Major neurological disease

• Uncontrolled systemic arterial hypertension

• MRI contraindications

• Non-acceptance of participation via informed consent